- Case report
- Open Access
Ocular melanoma in a patient successfully treated for diffuse malignant peritoneal mesothelioma: a case report
© Langlais et al.; licensee BioMed Central Ltd. 2012
Received: 12 January 2012
Accepted: 21 May 2012
Published: 21 May 2012
Diffuse malignant peritoneal mesothelioma and ocular melanoma are both rare tumors. To the best of our knowledge there is only one previous report of three cases in a family with known susceptibility to malignancies associating diffuse malignant peritoneal mesothelioma and ocular melanoma, with no sporadic cases previously reported.
We describe the case of a 59-year-old man with a history of diffuse malignant peritoneal mesothelioma, who presented with ocular melanoma 41 months after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. We also briefly review the literature.
Diffuse malignant peritoneal mesothelioma is an uncommon but aggressive disease. As diffuse malignant peritoneal mesothelioma characteristically remains confined to the abdominal cavity, any new extra-abdominal symptom should eventually raise suspicion of another primary tumor. Few cases of diffuse malignant peritoneal mesothelioma associated with other primary tumors have been reported. As ocular melanoma is also infrequent, we suspect a genetic predisposition to these tumors. There is emerging evidence supporting the role of BAP1 mutations in the pathogenesis of these two neoplasias.
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare but aggressive tumor arising from the serosal lining of the peritoneal cavity. In industrialized countries, incidence rates of DMPM range between 0.5 and 1.7 cases per million in the general population . Using traditional treatment modalities such as systemic chemotherapy and palliative surgery, median survival is poor (about 12 months). For nearly a decade, a new approach combining aggressive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has dramatically improved median survival, and this has reached 5 years in some series .
We present the case of a patient with DMPM initially treated with this approach, who later developed ocular melanoma (OM). Few other primary tumors have been linked to DMPM. To the best of our knowledge there is only one previous study reporting three patients with DMPM and OM, all in the same family .
Our patient’s postoperative course was complicated by respiratory failure episodes (secondary to pleural effusions and pulmonary edema), a right subphrenic abscess and a lower limb deep venous thrombosis. Recovery was slow but complete and our patient was discharged after 6 weeks. He was then followed with a positron emission tomography-computed tomography (PET-CT) scan every 4 months for 1 year and then every 6 months. At 36 months after treatment (June 2009), a PET-CT scan showed no evidence of recurrence.
In November 2010, brachytherapy with an iodine-125 plaque at a total dose of 80 Gy to the apex of the tumor was performed. In October 2011 the tumor reduced in size to 2.9 mm in height and there was no sign of recurrence of DMPM or OM on PET-CT.
DMPM accounts for 30% of all malignant mesotheliomas . The median age at diagnosis is 65 to 69 years. Asbestos exposure is the major risk factor for peritoneal mesothelioma even though association is less strong than for pleural mesothelioma, especially in women. Infection by the simian tumor virus (SV-40) and prior radiation exposure may also play a role in pathogenesis of DMPM .
DMPM can be divided into three histologic subtypes: epithelial (most common), sarcomatoid and biphasic (epithelial and sarcomatoid components). Immunohistochemistry is helpful to distinguish DMPM from other peritoneal cancers (colorectal adenocarcinoma and ovarian carcinoma, among others) . Metastatic papillary adenocarcinoma was the initial diagnosis in this case, which was later confirmed to be a DMPM by immunohistochemical studies.
Although there is no commonly accepted standard of care for DMPM, it is well established that CRS and HIPEC therapy has prolonged median survival: 12 months with palliative surgery and/or systemic chemotherapy versus nearly 5 years with CRS and HIPEC .
In the investigation of new symptoms in DMPM cases, clinicians must recall that DMPM characteristically tend to recur locally and therefore, extra-abdominal metastases are uncommon. The hypothesis of another primary tumor should be considered despite the few cases reported of DMPM associated with primary malignancies, especially in the context of lacking a history of asbestos exposure as in our case. A series of 500 cases of DMPM reported a 1.8% rate of DMPM associated with other primary tumors . In a multicenter study of 81 cases, a higher incidence (8.6%) was reported . Various types of cancer have been previously associated with DMPM (colorectal, breast, multiple myeloma, bronchogenic and bladder carcinomas) but none with a strong association [7–9].
Similar to DMPM, OM is an infrequent malignancy with an estimated annual incidence of six cases per million. It is the most common primary intraocular malignancy in adults, with the choroid affected in 90% of cases . Known risk factors include fair skin, light-colored eyes and the presence of pre-existing uveal nevus (our patient has the two former features) . Several genetic mutations in chromosomes 3, 6 and 8 have also been identified in association with OM . Current treatment includes brachytherapy for small and medium-sized tumors, with enucleation reserved for large tumors . An overall survival of 50% at 10 years is accepted.
The specific association between OM and mesothelioma has been previously described in three cases in a family with known susceptibility to malignancies. All cases were found to have a BAP1 mutation . BAP1 is a tumor suppressor gene located on chromosome 3p21 and the BAP1 protein is involved in DNA damage response, regulation of cell cycle and cell growth. Mutations in BAP1 are infrequent in the general population but high in mesothelioma (20.1%) and uveal melanoma (44.1%) [13–15]. The joint probability of the occurrence of both mesothelioma and OM in the same individual by chance has been estimated as 36 per trillion per year by Testa et al.  In that study, the authors found germline BAP1 mutations in 2 of 26 patients diagnosed with mesothelioma and both patients were previously diagnosed with uveal melanoma. Three of their four patients with uveal melanoma and BAP1 mutations subsequently developed mesothelioma. They have suggested a new BAP1-related cancer syndrome characterized by mesothelioma and ocular melanoma, and possibly other malignancies . In our patient, the mesothelioma was the presenting malignancy and 41 months later a choroidal melanoma was diagnosed. Clinicians should be aware of this entity since individuals who carry germline BAP1 mutations may be at increased risk of developing metachronously both OM and DMPM. Patients found with BAP1 mutations and their families should be closely monitored for the development of any or both of these malignancies for the possibility of early detection and intervention.
Patients with DMPM who undergo CRS and HIPEC can expect a longer life expectancy in comparison to patients treated by other therapeutic modalities. Nevertheless, the association of other primary cancer with DMPM may complicate the management and alter the prognosis for these patients.
To the best of our knowledge, this is the first known case report of DMPM and OM occurring in the same individual with no family history. This article is an important element to support the concept of a clinical correlation between DMPM and OM, probably as a BAP1-related cancer syndrome since the probability of the occurrence of both malignancies by chance in the same individual is extremely remote. Genetic testing for BAP1 mutations in this patient and his family is currently in progress and the results will be the subject of another publication.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Moolgavkar SH, Meza R, Turim J: Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control. 2009, 20: 935-944. 10.1007/s10552-009-9328-9.View ArticlePubMedGoogle Scholar
- Sugarbaker PH, Yan TD, Stuart OA, Yoo D: Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006, 32: 686-691. 10.1016/j.ejso.2006.03.012.View ArticlePubMedGoogle Scholar
- Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M: GermlineBAP1mutations predispose to malignant mesothelioma. Nat Genet. 2011, 43: 1032-1035.View ArticleGoogle Scholar
- Sideris L, Mitchell A, Drolet P, Leblanc G, Leclerc YE, Dubé P: Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg. 2009, 52: 135-141.PubMed CentralPubMedGoogle Scholar
- Chua TC, Yan TD, Morris DL: Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg. 2009, 52: 59-64.PubMed CentralPubMedGoogle Scholar
- Hesdorffer ME, Chabot J, DeRosa C, Taub R: Peritoneal mesothelioma. Curr Treat Options Oncol. 2008, 9: 180-190. 10.1007/s11864-008-0072-2.View ArticlePubMedGoogle Scholar
- Attanoos RL, Thomas DH, Gibbs AR: Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals. Histopathology. 2003, 43: 387-392. 10.1046/j.1365-2559.2003.01685.x.View ArticlePubMedGoogle Scholar
- Manzini Vde P, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M: Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010, 21: 348-353. 10.1093/annonc/mdp307.View ArticlePubMedGoogle Scholar
- Hayashi Y, Mizuo K, Hayashi K: An autopsy case of double cancer of multiple myeloma and malignant mesothelioma. Nippon Naika Gakkai Zasshi. 1989, 78: 1611-1612. 10.2169/naika.78.1611.View ArticlePubMedGoogle Scholar
- Hurst EA, William Harbour J, Cornelius LA: cular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol. 2003, 139: 1067-1073.View ArticlePubMedGoogle Scholar
- Singh AD, Bergman L, Seregard S: Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005, 18: 75-84. 10.1016/j.ohc.2004.07.002.View ArticlePubMedGoogle Scholar
- Margo CE: The collaborative ocular melanoma study: an overview. Cancer Control. 2004, 11: 304-309.PubMedGoogle Scholar
- Goldstein AM: GermlineBAP1mutations and tumor susceptibility. Nat Genet. 2011, 43: 925-926. 10.1038/ng.956.PubMed CentralView ArticlePubMedGoogle Scholar
- Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rütten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR: Germline mutations inBAP1predispose to melanocytic tumors. Nat Genet. 2011, 43: 1018-1021. 10.1038/ng.910.PubMed CentralView ArticlePubMedGoogle Scholar
- Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM: Frequent mutation ofBAP1in metastasizing uveal melanomas. Science. 2010, 330: 1410-1413. 10.1126/science.1194472.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.